Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%

MT Newswires Live07-31

Brii Biosciences (HKG:2137) does not expect any effect on its operations or finances due to the initiation of restructuring procedures under the "Companies' Creditors Arrangement Act" by one of its partners, VBI Vaccines, a Wednesday filing with the Hong Kong Exchange said.

The company also disclosed in the filing that it has already reserved a worldwide exclusive license to BRII-179 and the exclusive rights of PreHevbri in Asia Pacific regions excluding Japan, which it obtained from VBI on July 6, 2023, leaving the company unaffected by the indebtedness of VBI.

The company's shares were up 3% in recent trade.

Price (HKD): $1.02, Change: $+0.03, Percent Change: +3.03%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2455794429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-31 15:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2455794429","market":"us","top_or_hot":-1,"title":"Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> Brii Biosciences (HKG:2137) does not expect any effect on its operations or finances due to the initiation of restructuring procedures under the \"Companies' Creditors Arrangement Act\" by one of its partners, VBI Vaccines, a Wednesday filing with the Hong Kong Exchange said.</p><p>The company also disclosed in the filing that it has already reserved a worldwide exclusive license to BRII-179 and the exclusive rights of PreHevbri in Asia Pacific regions excluding Japan, which it obtained from VBI on July 6, 2023, leaving the company unaffected by the indebtedness of VBI.</p><p>The company's shares were up 3% in recent trade.</p><p>Price (HKD): $1.02, Change: $+0.03, Percent Change: +3.03%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Says Unaffected by VBI Vaccines' Restructuring Under Creditors Arrangement Act, Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-31 15:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Brii Biosciences (HKG:2137) does not expect any effect on its operations or finances due to the initiation of restructuring procedures under the \"Companies' Creditors Arrangement Act\" by one of its ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2455794429","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2455794429","pubTimestamp":1722409535,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Brii Biosciences  does not expect any effect on its operations or finances due to the initiation of restructuring procedures under the \"Companies' Creditors Arrangement Act\" by one of its partners, VBI Vaccines, a Wednesday filing with the Hong Kong Exchange said.The company also disclosed in the filing that it has already reserved a worldwide exclusive license to BRII-179 and the exclusive rights of PreHevbri in Asia Pacific regions excluding Japan, which it obtained from VBI on July 6, 2023, leaving the company unaffected by the indebtedness of VBI.The company's shares were up 3% in recent trade.Price : $1.02, Change: $+0.03, Percent Change: +3.03%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK4139":"生物科技","BK4526":"热门中概股","BK4588":"碎股","HKD":"尚乘数科","BK4023":"应用软件","VBIV":"VBI Vaccines Inc.","BK4585":"ETF&股票定投概念","02137":"腾盛博药-B","BK1587":"次新股"},"translate_title":"Brii Biosciences表示不受VBI Vaccines根据债权人安排法案进行重组的影响，股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HKD":1,"VBIV":1,"02137":0.9},"content_text":"Brii Biosciences (HKG:2137) does not expect any effect on its operations or finances due to the initiation of restructuring procedures under the \"Companies' Creditors Arrangement Act\" by one of its partners, VBI Vaccines, a Wednesday filing with the Hong Kong Exchange said.The company also disclosed in the filing that it has already reserved a worldwide exclusive license to BRII-179 and the exclusive rights of PreHevbri in Asia Pacific regions excluding Japan, which it obtained from VBI on July 6, 2023, leaving the company unaffected by the indebtedness of VBI.The company's shares were up 3% in recent trade.Price (HKD): $1.02, Change: $+0.03, Percent Change: +3.03%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2455794429"}